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a b s t r a c t
Human dialyzable leukocyte extracts (DLEs) are heterogeneous mixtures of low-molecular-weight pep-
tides that modulate immune responses in various diseases. Due their complexity, standardized methods
to identify their physicochemical properties and determine that production batches are biologically
active must be established. We aimed to develop and validate a size exclusion ultra performance
chromatographic (SE-UPLC) method to characterize TransferonTM, a DLE that is produced under good
manufacturing practices (GMPs). We analyzed an internal human DLE standard and 10 representative
batches of TransferonTM, all of which had a chromatographic proﬁle characterized by 8 main peaks and a
molecular weight range between 17.0 and 0.2 kDa. There was high homogeneity between batches withuality speciﬁcations
FN-gamma
ransferon
regard to retention times and area percentages, varying by less than 0.2% and 30%, respectively, and the
control chart was within 3 standard deviations. To analyze the biological activity of the batches, we stud-
ied the ability of TransferonTM to stimulate IFN- production in vitro. TransferonTM consistently induced
IFN- production in Jurkat cells, demonstrating that this method can be included as a quality control step
in releasing TransferonTM batches. Because all analyzed batches complied with the quality attributes that
were evaluated, we conclude that the DLE TransferonTM is produced with high homogeneity.
201©Abbreviations: IFN-, interferon gamma; HPLC, high-performance liquid chro-
atography; UPLC, ultra-performance liquid chromatography; SE, size exclusion;
P, reverse-phase; GMPs, good manufacturing practices; SD, standard deviation;
SD, relative standard deviation; DLE, dialyzable leukocyte extract; Da, daltons;
F-B, nuclear factor kappa B; cAMP, cyclic adenosine monophosphate; TNF-,
umor necrosis factor alpha; IL-6, interleukin 6;DTH, delayed-typehypersensitivity;
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1. Introduction
Human dialyzable leukocyte extracts (DLEs) are heterogeneous
mixtures of low-molecular-weight peptides (<10kDa) that are
released on disruption of peripheral blood leukocytes from healthy
donors [1]. Administration of DLEs improves clinical responses in
infections [2,3], allergies [4], cancer [5,6], and immunodeﬁciencies
[7].
The therapeutic and adjuvant effects of DLEs are associated
with their ability to modulate immune responses in the above
mentioned diseases (for detailed reviews see Refs. [8,9]). DLEs
alter innate signaling pathways, such as TLRs, NF-B, and cAMP in
cultured immune cells [10]. Consequently, DLEs stimulate the pro-
duction of proinﬂammatory cytokines, including TNF-, IL-6 [11],
and IFN- [12].
Despite the positive clinical effects of DLEs, their complex-
ity has impeded full characterization of their components and
Open access under CC BY-NC-ND license.active substances. Thus, characterization, total protein per dose,
and efﬁcacy of DLEs have never been reported, necessitating the
development and validation of suitable methods that analyze their
physicochemicalproperties. In addition, suchmethodswouldallow
 license.
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stablishing the relationship between the physicochemical proper-
ies and expected biological activities of DLEs.
The seminal reports on the physicochemical characterization
f DLEs have applied chromatographic methods. In 1962, Baram
nd Mosko used reverse-phase (RP) chromatography to demon-
trate that DLEs are a heterogeneousmixture that comprise diverse
hromatographic fractions [13]. This group also observed that DLEs
enerated 10 peaks by size exclusion chromatography—the ﬁfth
eak, containing molecules under 10kDa, harbored most of the
iological effects [14,15].
Similarly, Vandenbark and colleagues [16], Burger and col-
eagues [17], and Khan and colleagues [18] noted that speciﬁc
ubfractions, obtained by high-performance liquid chromatog-
aphy (HPLC), RP-HPLC, and anion-exchange chromatography,
espectively, mediated the effects of DLEs. The active fraction was
usceptible to proteases [17], and its physicochemical properties
uggested high protein content [18]. On further analysis of the
ctive fractions of the DLEs, the most abundant amino acids were
ly, Ser, and Glu, whereas Lys and aromatic amino acids were the
east abundant [19].
Kirkpatrick and colleagues provided deﬁnitive evidence that the
eptidic contentmediates the biological activity in DLEs. They frac-
ionated DLEs by RP-HPLC and isolated peptides that contained the
equence MXLLYAQDL/VEDN. Administration of blocking peptides
nhibited the characteristic transfer of delayed type hypersensitiv-
ty (DTH) by DLEs [20]. Collectively, these reports demonstrate that
LEsareaheterogeneousmixtureofpolar andhydrophilicpeptides
ith molecular weights below 10kDa.
DLEs are produced and commercialized worldwide.
ransferonTM is a DLE manufactured by the National School
f Biological Sciences (ENCB), National Polytechnic Institute (IPN),
exico, at GMP facilities. TransferonTM is registered by Mexican
ealth authorities as a drug and commercialized nationally. Simi-
arly, other DLEs are registered as drugs in China, Cuba, and Czech
epublic [21–23]. Based on the signiﬁcance of chromatographic
ethods in developing and characterizing DLEs and the lack of a
tandard physicochemical method to analyze them, we aimed to
evelop and validate an UPLC approach to examine TransferonTM.
e identiﬁed a typical chromatographic proﬁle with eight main
eaks.
We also assessed the batch-to-batch reproducibility of 10
epresentative batches of TransferonTM by analyzing their phys-
cochemical properties and their ability to effect IFN- secretion
n vitro. All batches met the quality control standard with regard to
eptide concentration, molecular weight rate, time of retention of
ain peaks, and efﬁcacy.
. Materials and methods
.1. Analytical samples and peptide quantiﬁcation
Samples of TransferonTM were obtained from 10 typical batches
10K02B, 10K04A, 11A01E, 11A01C, 11A02D, 11A02E, 11A02F,
1A02G, 11E01, and 12A01) produced by UDIMEB at GMP facilities
sing amodiﬁedversionof themethodof Borkowsky and Lawrence
24]. Brieﬂy, leukocytes were lysed with 5 freeze-thaw cycles,
nd dialysis was performed using a 12-kDa membrane to obtain
ow-molecular-weight peptides in the permeate. The peptide con-
entrationwasmeasuredbybicinchoninic acid (BCA)methodusing
he Pierce BCA kit (Thermo Fisher Scientiﬁc; Massachusetts, USA)
ccording to the manufacturer’s instructions [25]. Internal batch
attern of TransferonTM was deﬁned as an internal batch that has
een approved satisfactorily all the quality control tests speciﬁed
or the product (endotoxin content, microbiologic test, characteri-
ation, protein content and biological activity).and Biomedical Analysis 88 (2014) 289–294
2.2. Chromatographic methods
We performed SE-UPLC on an H class AcquityTM UPLC sys-
tem (WatersTM; Massachusetts, USA) that was controlled by
EmpowerTM (WatersTM) using an Acquity BEH 125 molecular size
exclusion column (1.7m×4.6×150mm) (WatersTM) at 30 ◦C.
The chromatograms were generated on a tunable ultraviolet (TUV)
detector (WatersTM) at 280nm with an isocratic workﬂow of
0.4ml/min of monobasic/dibasic sodium phosphate-buffered solu-
tion (pH 6.8, 50mM; Mallinckdrodt Baker; Pennsylvania, USA),
sodium chloride 150mM (Mallinckdrodt Baker) and ultrapure
Milli Q water (Millipore, Darmstadt, Germany). The run time was
15min.
2.3. Characterization analysis: SE-UPLC
SE-UPLC is considered as a characterization method per the
International Conference of Harmonization (ICH) [26]. The method
was validated by testing system suitability, precision, and speci-
ﬁcity. We used a gel ﬁltration standard (Bio-RadTM; California,
USA) spiked with l-tryptophan BioUltra (Sigma Aldrich; Missouri,
USA) as molecular weight standard. To analyze the batch-to-batch
reproducibility, TransferonTM samples were compared against an
internal batch pattern (1.5mg/ml); each sample was injected in
duplicate (1l for standards and 3l for TransferonTM samples).
The chromatographic proﬁles were analyzed using EmpowerTM
(ApexTrack method) to obtain the area percentage and retention
time for each peak.
2.4. Biological activity
The efﬁcacy of TransferonTM was determined in Jurkat clone
E6-1 cells (ATCC; Manassas, VA, USA). Brieﬂy, 3×105 cells were
plated in 24-well plates and maintained in RPMI 1640 medium
(ATCC; Virginia, USA) that was supplemented with fetal bovine
serum (GibcoTM, Life Technologies; New York, USA). Cultures were
stimulated with TransferonTM (0.1, 1, or 10g/ml) or type IV-S
concanavalin A (25g/ml; Sigma–Aldrich; Missouri, USA) as a pos-
itive control. After 72h, IFN- was measured in the supernatant
using the BDOptEIA-IFN ELISA kit (Becton Dickinson Biosciences;
California, USA) by triplicate. After stimulation, 100l of standard
or sampleweremixedwith50l of PBSwith10%ofheat inactivated
FBS and incubated for two hours in capture antibody-coated wells.
After extensive washing, 100l of a solution including a biotiny-
lated detection antibody and streptavidin-horseradish peroxidase
were added to eachwell and incubated for one hour. Afterwashing,
the reactions were developed with 3,3′5,5′-Tetramethylbenzidine
(TMB) plus hydrogen peroxide, stopped, and read immediately
at 450nm [27]. IFN- quantiﬁcation above the detection limit
(4.7 pg/ml) was considered as positive, since basal production of
this cytokine in Jurkat cells was undetectable.
2.5. Data analysis
To analyze the homogeneity in chromatographic proﬁles
between TransferonTM batches, we calculated the average,
standard deviation, and percentage standard deviation for the peak
areas and retention times. We also calculated the average and
standard deviation for peptide content and IFN-.
3. Results and discussionDLEs and their clinical activity have been described since 1954
[28], but their batch-to-batch reproducibility in GMP facilities has
not been examined. We analyzed 10 batches of TransferonTM with
E. Medina-Rivero et al. / Journal of Pharmaceutical and Biomedical Analysis 88 (2014) 289–294 291
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Table 1
Validation parameters for the SE-UPLC identitymethod developed for TransferonTM.
Parameter Acceptance criteria Result
System suitability
Tailing factor less than
1.75
Tailing factor 1.44–1.51
Relative retention time
(against B12 vitamin)
of:
Relative retention
time:
Mioglobulin
0.67±0.05 SD
Mioglobin 0.67±0.00
Ovoalbumin
0.56±0.05 SD
Ovoalbumin
0.57±0.00
Method accuracy Variation of areas
between batches
lectures are less than
3.0%
%RSD 0.45–1.76
System accuracy Variation of areas
between three
standard lectures are
less than 3.0%
%RSD 1.15–2.28
Speciﬁcity Correspondence
between internal batch
Chromatographic
proﬁles of batches are
Next, we compared the area percentages and retention times
of the 8 main peaks to analyze batch-to-batch reproducibility. The
%RSD for all area percentages was below 30% (Table 2) and var-
ied within 3 SD (data not shown). This variation is accepted as a
Table 2
Comparison of area percentages of the eight main peaks in TransferonTM chromato-
graphic proﬁle between batches.
BATCH P1 P2 P3 P4 P5 P6 P7 P8
1 10K02B 4.2 14.75 3.45 17.55 23.1 13.7 1.35 21.4
2 10K04A 5.4 24.55 2.85 14.3 24.15 9 0.9 17.7
3 11A01B 8.85 26.15 2.5 11.95 24.9 10.8 0.75 13.6
4 11A01C 8.85 14.65 3.3 15.05 24.2 12.35 0.7 20.5
5 11A02D 5.7 22.5 2.95 12.45 27.4 9.9 0.6 17.45
6 11A02E 5.45 23.35 2.3 11.2 31.15 10.25 0.75 14.35
7 11A02F 6.3 25.65 2.7 10.05 29.4 10.25 0.7 13.75
8 11A02G 5.35 23.7 2.3 10.85 32.05 10.35 0.7 13.7ig. 1. Analysis of protein content between TransferonTM batches. Protein concen-
ration, quantiﬁed by BCA method, is speciﬁed for each batch (squares). Theorical
alue (solid line) and ±3SD interval (dashed lines) are shown.
egard to protein content, characterization by SE chromatography-
PLC, and activity in an in vitro model of IFN- production. The
atches were typical production batches from 2010 and 2011.
Early reports obtained DLEs on a low scale using cells from
atient-related or DTH-positive donors [13]. In these studies, dose
as calculated in arbitrary units that were related to the num-
er of leukocytes of origin [29]. In contrast, each TransferonTM
atch is produced from a pool of 1000 healthy donors in order
o reduce donor-to-donor variability [30]. Further, the active prin-
iple per dose in TransferonTM is quantiﬁed as protein content,
s reported [31,32]. TransferonTM contains 2mg of peptides in
ml of excipient. By analysis of protein content in 10 batches,
ransferonTM had an average content of 0.433mg/ml, which rep-
esent a 108.2% regarding to the theoretical expected value of
.40mg/ml. However, this percentage meets the criteria estab-
ished in the speciﬁcation for TransferonTM, which is from 0.34 to
.46mg/ml. The variation in concentrations between batches was
ithin ±3 SD (Fig. 1), demonstrating that the process by which
ransferonTM is produced consistently generates batches that are
omogeneous with regard to protein content.
.1. SE-UPLC characterization method
According to the FDA’s Guide for Biological Products and
exican Pharmacopeia, biological drugs for clinical use require
haracterization of the active principle during production and as
art of the ﬁnal quality control step [33,34]. Since TransferonTM is
urrently as project to be included in the Mexican Pharmacopeia,
e used chromatography,which is a generalmethod for drug char-
cterization [33,34]. We developed a characterization method for
ransferonTM using SE-UPLC. We choose to use columns with a
25 A˚ pore size particles (suitable for low molecular weight pep-
ides separation) and tested two column lengths: 150 and 300mm.
he resolution factor (˛) for peaks 3 and4was 1.02 and1.08 respec-
ively for 150mm column, and 1.45 and 1.50 for 300mm column.
espite of the better resolution in the 300mm column, peaks 1, 3
nd4werenotbase resolved.Becauseof that, sizeexclusioncolumn
f 150mm was established for routine release analysis in quality
ontrol laboratory.
To validate the assay, we analyzed its suitability, accuracy, and
peciﬁcity (Table 1). The system’s suitability was examined by
omparing the retention times for molecules with known molec-
lar weights (standards) and calculating the tailing factor. To
tudy the accuracy of the method and system, we calculated thepattern and batches of
TransferonTM
equal to internal batch
pattern standard
variations in peak areas between batches and between 3 standard
lectures. In both cases the variation was less than 3 SD. Speci-
ﬁcity was evaluated by comparing samples with our internal
standard of TransferonTM. The chromatographic proﬁles of the
batches were the same as that of the internal batch pattern. These
data demonstrate that our characterization assay meets the min-
imum requirements for qualitative physicochemical methods, as
indicated by the International Conference on Harmonization [26].
With this validated method, we analyzed 10 typical batches of
TransferonTM at the moment of release. Because DLEs are a com-
plex mixture of peptides, they generate multiple chromatographic
peaks. Other studies have reported 4, 7, and 13 peaks for DLEs that
have been produced by similar processes [35–39]. In our assay,
TransferonTM generated 8main peaks, as did the internal batch pat-
tern. The difference between our data and the earlier reports can be
explained by disparities in the sensitivity of the chromatographic
methods [40].
All peaks of TransferonTM were shown in the range of 17kDa
(equine myoglobine) to 0.2 kDa (tryptophan) (Fig. 2A). The ﬁfth
peak had the largest area (28.09%), while the seventh peak had the
minor area (0.77%). These properties are consistent with a product
that has been dialyzed against a 12kDa membrane, such as DLEs
[24].9 11E01 3.4 20.2 1.55 10.45 35.3 15.55 0.65 11.45
10 12A01 7 28.35 1.35 12.1 29.2 8.6 0.6 10.65
MEAN 6.05 22.39 2.53 12.6 28.09 11.08 0.77 15.46
%RSD 29.41 20.56 27.07 18.76 14.35 19.58 28.75 23.59
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Fig. 2. SE-UPLC chromatographic proﬁle of TransferonTM. A. Comparison between a representative batch of TransferonTM (solid line) and molecular weight standards (dashed
line), showing that the eight main peaks of TransferonTM have retention times between those of equine myoglobin (17.0 kDa) and tryptophan (0.23kDa). Other peaks in
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ethical, timing, and commercial reasons. For example, the activ-
ity of DLEs has been demonstrated by inducing DTH in mice [46]
or analyzing their effects on leukocyte migration [47]. Although
Table 3
Comparison of retention times of the eight main peaks in TransferonTM chromato-
graphic proﬁle between batches.
BATCH P1 P2 P3 P4 P5 P6 P7 P8
1 10K02B 4.7 4.9 5.49 5.76 5.94 6.42 7.19 8.04
2 10K04A 4.68 4.9 5.5 5.76 5.94 6.43 7.2 8.05
3 11A01B 4.66 4.89 5.49 5.76 5.95 6.43 7.21 8.07
4 11A01C 4.66 4.9 5.49 5.76 5.95 6.43 7.21 8.06
5 11A02D 4.68 4.9 5.49 5.75 5.93 6.42 7.21 8.06
6 11A02E 4.68 4.9 5.49 5.75 5.94 6.43 7.21 8.06
7 11A02F 4.68 4.9 5.48 5.75 5.94 6.42 7.21 8.06
8 11A02G 4.68 4.9 5.49 5.75 5.94 6.42 7.22 8.06he standard correspond to tryglobulin/gamma-globulin (>80kDa), ovoalbumin (4
mpowerTM (ApexTrack method) to obtain the area percentage and retention time
n internal human DLE standard (below). All batches showed homogeneity in the t
uality speciﬁcation of a biological product by regulatory agencies
nd allows the product to have a biological activity. For example,
he European Pharmacopeial speciﬁcation of erythropoietin iso-
orm 6 has a range from 10% to 35% area, showing 50% variation
41]. Similarly, the variation in retention times for each peak from
atch to batch was below 0.2% (Table 3) and varied within 3 SD
data not shown). Area percentages and retention times depend
n the physicochemical attributes of a product; thus, our results
ndicate that the homogeneity between TransferonTM batches can
e tracked for at least 2 years, complyingwith theminimumquality
ontrol standards for the pharmaceutical industry [42].
.2. Biological activity
Efﬁcacy is an essential attribute of a therapeutic drug, and its
ctivity is expected to be preserved between commercial batches
33]. DLEs have demonstrated activity in clinical trials from the
ast 50 years [2,8,43–45], but only recently they have begun to
e produced by GMPs, necessitating the development of tests that
valuate their activity and batch release.a), and B12 vitamin (1.35kDa). The chromatographic proﬁles were analyzed using
ch peak. B. Representative identity test for TransferonTM (above) compared against
s: Absorbance Units.
To this end, animal models and in vitro assays are preferred for9 11E01 4.7 4.9 5.48 5.75 5.94 6.43 7.22 8.07
10 12A01 4.67 4.89 5.49 5.76 5.94 6.42 7.2 8.05
MEAN 4.68 4.90 5.49 5.76 5.94 6.43 7.21 8.06
%RSD 0.21 0.08 0.11 0.17 0.07 0.07 0.13 0.11
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Fig. 3. Effect of TransferonTM on IFN- secretionby Jurkat cells. Cellswere treated for
72h with different TransferonTM batches, and the concentration of IFN- in super-
natants was quantiﬁed by ELISA (diamonds). Each experiment included positive
(25g/ml concanavalin A) and negative (vehicle) controls (not shown). All batches
induced IFN- secretion above the method’s detection limit (dashed line). Data are
shown as mean± SEM (triplicates).
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and characterizationof immunopeptide fromdialyzable leukocyte extract, Cell.nimal models reﬂect the complexity of a drug response in a whole
rganism,we developed an in vitro assay as a quality control for the
elease of TransferonTM batches to avoid the variability between
nimal models, minimize the number of animals that is employed
uring TransferonTM production, and reduce the analysis time.
DLEs upregulate IFN- in lymphocytes [48], and our assay ana-
yzed the ability of a lymphocytic cell line (Jurkat clone E6-1)
o produce IFN- in response to TransferonTM. Our positive and
egative controls were concanavalin A- and vehicle-treated cells,
espectively. All batches induced IFN- production to levels above
he detection limit (4.7 pg/ml; Fig. 3) and within 3 SD (data not
hown). These results contrast previous attempts todevelop in vitro
ssays to evaluate DLE activity, such as leukocyte proliferation [49].
Thus, all analyzed batches shared physicochemical properties
nd consistently generated a biological response—i.e., IFN- pro-
uction.
. Conclusions
Our analysis of 10 batches of TransferonTM, produced in GMP
acilities, demonstrates that is possible to produce a mixture of
eptides that have been extracted from complex raw materials,
uch as lysed human leukocytes, with high batch-to-batch repro-
ucibility. The 10 batches compliedwith quality standards for their
ttributes, such as peptide concentration in the ﬁnal dose, molecu-
ar weight, time of retention of the main peaks, and activity. Thus,
ransferonTM is a DLE that observe the government normativity
equired for hemoderivatives used for clinical use, including batch-
o-batch reproducibility.
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